Do you want to read an article? Please log in or register.
Tissue exposure does not explain non-response in ulcerative colitis patients with adequate serum vedolizumab concentrations
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis: Ustekinumab PK and exposure-response in UC
Clin Gastroenterol Hepatol.
Adedokun OJ, Xu Z, Marano C, O'Brien C, Szapary P, Zhang H, Johanns J, Leong RW, Hisamatsu T, van Assche G, Danese S, Abreu MT, Sands BE, Sandborn WJ
doi: 10.1016/j.cgh.2019.11.059.
Inflammatory Bowel Disease
A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis
Inflamm Bowel Dis.
Dreesen E, Kantasiripitak W, Detrez I, Stefanović S, Vermeire S, Ferrante M, Bouillon T, Drobne D, Gils A
doi: 10.1093/ibd/izz144.
Inflammatory Bowel Disease
Deep remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis
J Crohns Colitis.
Sandborn WJ, Colombel JF, Panaccione R, Dulai PS, Rosario M, Cao C, Barocas M, Lasch K
doi: 10.1093/ecco-jcc/jjy149.
RECOMMENDED
Inflammatory Bowel Disease
Vedolizumab Efficacy, Safety, and Pharmacokinetics with Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients with Crohn's Disease or Ulcerative Colitis
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis.
Vermeire S, Lukáš M, Magro F, Adsul S, Lindner D, Rosario M, Roth J, Danese S
doi: 10.1093/ecco-jcc/jjaa027.
Inflammatory Bowel Disease
Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial
Lancet Gastroenterol Hepatol.
Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, Nurmohamed M, Bossuyt PJJ, Bodelier A, Rispens T, van Megen YJB, D'Haens GR
doi: 10.1016/S2468-1253
Inflammatory Bowel Disease
Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1
Inflamm Bowel Dis.
Reinisch W, Bressler B, Curtis R, Parikh A, Yang H, Rosario M, Røseth A, Danese S, Feagan B, Sands BE, Ginsburg P, Dassopoulos T, Lewis J, Xu J, Wyant T
doi: 10.1093/ibd/izy304.
Inflammatory Bowel Disease
Shorter Disease Duration is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease but Not Ulcerative Colitis
Clin Gastroenterol Hepatol.
Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland B, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV Jr, Sands BE, Colombel JF, Dulai PS, Ungaro R
doi: 10.1016/j.cgh.2018.12.040.
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
Am J Gastroenterol.
Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS
doi: 10.1038/s41395-018-0162-0.
COMMENTED
Inflammatory Bowel Disease
Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis
Inflamm Bowel Dis.
Battat R, Dulai PS, Vande Casteele N, Evans E, Hester KD, Webster E, Jain A, Proudfoot JA, Mairalles A, Neill J, Singh S, Chang JT, Rivera-Nieves J, Sandborn WJ, Boland BS
doi: 10.1093/ibd/izy307.